Incidence of Hypoxia During Intravitreal Anti-VEGF (Vascular Endothelial Growth Factor) Injections for Retinopathy of Prematurity (ROP) Under Topical Anesthesia
Recruiting
Observational Study
Retinopathy of Prematurity
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Any
- Study type
- Observational
- Participants needed
- 74 (estimated)
- Sponsor
- Minia University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Purpose:
To evaluate the incidence and severity of hypoxia and address a genuine evidence gap focusing on intraprocedural hypoxia during bedside intravitreal ranibizumab injection for retinopathy of prematurity (ROP), an area that has been only sparsely investigated in premature infants treated across multiple hospitals in the Al Qassim region of Saudi Arabia
Methods:
A retrospective multicente…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion criteria
* Premature infants with treatment-requiring ROP.
* Treatment with intravitreal ranibizumab.
* Complete procedural monitoring records, including continuous pulse oximetry.
* Availability of follow-up data after treatment. Exclusion criteria
Infants were excluded if they had:
* …
Contacts